Skip to main content
SpringerLink
Log in

Current Role of Anthracyclines in the Treatment of Multiple Myeloma

  • Chapter
Myeloma Therapy

Part of the book series: Contemporary Hematology ((CH))

  • 534 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chu E, DeVita VC. Physician's cancer chemotherapy drug manual. Sudbury, MA: Jones and Bartlett; 2006.

    Google Scholar 

  2. Robert J. Anthracyclines. In: A clinician's guide to chemotherapy pharmacokinet-ics and pharmacodynamics. Vol. 93 (3rd edition). Baltimore, MD: Williams 8 Wilkins; 1983.

    Google Scholar 

  3. Sharpe M, Easthope SE, Keating GM, et al. Polyethylene-glycol-liposomal doxoru-bicin: A review of its use in the management of solid and hematological malignancies and AIDS-related kaposi's sarcoma. Drugs. 2002;62:2089–2126.

    Article  PubMed  CAS  Google Scholar 

  4. Gabizon AA. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001;19:424–436.

    Article  PubMed  CAS  Google Scholar 

  5. Hussein MA, Wood L, Hsi E, et al. A phase II trial of pegylated liposomal doxo-rubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer. 2002;95:2160–2168.

    Article  PubMed  CAS  Google Scholar 

  6. Lee CC, Gillies ER, Fox ME, et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. PNAS. 2006;103:16649–16654.

    Article  PubMed  CAS  Google Scholar 

  7. Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466.

    Article  PubMed  CAS  Google Scholar 

  8. Doroshow JH. Anthracyclines and anthracenediones. In: Cancer chemotherapy and biotherapy: Principles and practice. Vol. 500 (3rd edition). Philadelphia, PA: Lippincott Williams 8 Wilkins; 2001.

    Google Scholar 

  9. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003;22:7340.

    Article  PubMed  Google Scholar 

  10. Alexanian R, Barlogie B, Tucker S VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33:86–89.

    Article  PubMed  CAS  Google Scholar 

  11. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet. 1989;2: 882–885.

    Article  PubMed  CAS  Google Scholar 

  12. Rifkin RM, Gregory SA, Mohrbacher A, et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma. Cancer. 2006;106:848–858.

    Article  PubMed  CAS  Google Scholar 

  13. Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. Ann Oncol. 2004;15:134–138.

    Article  PubMed  CAS  Google Scholar 

  14. Offidani M, Corvatta L, Piersantelli M, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood. 2006;108:2159–2164.

    Article  PubMed  CAS  Google Scholar 

  15. Deauna-Limayo D Aljitawi O, Mayo M, et al. Pegylated liposomal doxorubicin (Doxil®), dexamethasone and low dose thalidomide (DDt) as therapy for newly diagnosed multiple myeloma. Blood. 2005;106:Abstract 5164.

    Google Scholar 

  16. Orlowski RZ, Baldwin AS Jr. NF-kappa B as a therapeutic target in cancer. Trends Mol Med. 2002;8:385–389.

    Article  PubMed  CAS  Google Scholar 

  17. Ma MH, Yang HH, Parker K, et al. The proteasome prohibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136–1144.

    Google Scholar 

  18. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood. 2003;101:2377–2380.

    Article  PubMed  CAS  Google Scholar 

  19. Orlowski RZ, Peterson BL, Sanford B, et al. Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for adult patients with symptomatic multiple myeloma: Cancer and leukemia group B study 10301. Blood. 2006;108:Abstract 797.

    Google Scholar 

  20. Jakubowiak AJ, Brackett L, Kendall T, et al. Combination therapy with Velcade, Doxil, and Dexamethasone (VDD) for patients with relapsed/refractory multiple myeloma (MM). Blood. 2005;106:Abstract 5179.

    Google Scholar 

  21. Jakubowiak A, Al-Zoubi A, Kendall T, et al. Combination therapy with bortezomib(Velcade®), Doxilê, and dexamethasone(VDD) in newly diagnosed myeloma: updated results of phase II clinical trial. Haematologica. 2007;92:Abstract PO-721.

    Google Scholar 

  22. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353–1356.

    Article  PubMed  CAS  Google Scholar 

  23. Palva IP, Ahrenberg P, Ala Harja K, et al. Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish leukaemia group. Eur J Haematol. 1990;44:121–124.

    Article  PubMed  CAS  Google Scholar 

  24. Hussein MA, Elson P, Tsoe EA, et al. Doxil (D), vincristine (V), decadron (d) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM). Blood [abstract]. 2002;100:403a.

    Article  Google Scholar 

  25. Baz R, Choueiri TK, Abou Jawde R, et al. Doxil (D), Vincristine (V), reduced frequency Dexamethasone (d) and Revlimid(R) (DVd-R) results in a high response rate in patients with refractory multiple myeloma (RMM). Blood. 2005;106: Abstract 2559.

    Google Scholar 

  26. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematological malignancies. Blood. 2005;105:3058–3065.

    Article  PubMed  CAS  Google Scholar 

  27. Orlowski RZ, Zhuang SH, Parekh T, et al. The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: results from a planned interim analysis of a randomized phase III study. Blood. 2006;108: Abstract 404.

    Google Scholar 

  28. Chanan-Khan AA, Padmanabhan S, Miller KC, et al. Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response rate in patients (pts) with relapsed (rel) or refactory (ref) multiple myeloma. Blood. 2006;108:Abstract 3539.

    Google Scholar 

  29. San-Miguel JF, Hajek R, Nagler A, et al. Doxil®+Velcadeê in previously treated ≥ 65y myeloma pts. Haematologica. 2007;92:PO-620.

    Google Scholar 

  30. Ciolli S, Leoni F, Casini C, et al. Liposomal doxorubicin (Myocetê) enhance the efficacy of bortezomib, dexamethasone plus thalidomide in refractory myeloma. Blood. 2006;108:Abstract 5087.

    Google Scholar 

  31. Chari A, Kaplan L, Linker C, et al. Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma. Blood. 2005;106:Abstract 5182.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA

    Sikander Ailawadhi & Asher Chanan-Khan

Authors
  1. Sikander Ailawadhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Asher Chanan-Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Winship Cancer Institute, Emory University, B3307 Clifton Road, Atlanta, GA, 30322, USA

    Sagar Lonial MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ailawadhi, S., Chanan-Khan, A. (2008). Current Role of Anthracyclines in the Treatment of Multiple Myeloma. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-564-0_9

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-82-4

  • Online ISBN: 978-1-59745-564-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation